TP53 and colorectal carcinoma: It demonstrated its capabilities by identifying well-documented associations in TCGA CRC datasets, such as the enrichment of TP53 mutations in late-stage CRC and the association of KRAS mutations with poor progression-free survival in FOLFOX-treated patients.